Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: A pilot study
- 10 March 2020
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 82, 106375
- https://doi.org/10.1016/j.intimp.2020.106375
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Targeting TGF-β signaling in cancerEmerging Therapeutic Targets, 2013
- Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma PatientsJournal of Immunology Research, 2011
- Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccineVaccine, 2011
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- Therapeutic options for intermediate-advanced hepatocellular carcinomaWorld Journal of Gastroenterology, 2011
- Harnessing Dendritic Cells to Generate Cancer VaccinesAnnals of the New York Academy of Sciences, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinomaJournal of Hepatology, 2008
- Therapeutic Cancer VaccinesSurgical Oncology Clinics of North America, 2007
- Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma PatientsClinical Cancer Research, 2006